Pheochromocytomas might be sporadic or genetic. Genetic pheochromocytoma is associated with multiple endocrine neoplasia (MEN) type 2A, MEN type 2B, and von Hippel-Lindau (VHL) disease. RET mutations are identified in more than 90% of index cases of MEN2 and familial medullary thyroid cancer and in about 4-12% of apparent sporadic cases. Here, we report a 54-year-old man presenting with pheochromocytoma and renal cell carcinoma, who was identified as having a novel missense RET mutation.
The occurrence of pheochromocytoma might A whole-body scan with iodine-131-meta-iodobenzylguanidine (I-131 MIBG) was performed, which revealed focal tracer uptake in the right adrenal area and normal tracer uptake in other We performed genetic testing using the patient's blood to investigate mutations in RET and VHL genes. VHL tumor suppressor gene mutation analysis revealed no mutation; however, RET gene mutation analysis identified a novel missense mutation (exon 15, 2611G>A, Val871IIe) (Fig. 4) . RET immunostaining was negative for S-100 in renal cell carcinoma tissue, but pheochromocytoma tissue was positive (Fig. 3C ).
According to this result, we performed neck CT, which showed mild enlargement of both para- Although there are no prophylactic thyroidectomy guidelines regarding this novel missense RET mutation, we recommended total thyroidectomy for the left thyroid nodule. In the patho To conclude, we identified a new RET mutation in a patient presenting with pheochromocytoma and incidentally detected renal cell cancer. We suggest that sporadic pheochromocytoma with other malignant tumors might necessitate further evaluation by gene mutation screening.
